News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Erman Akkus: Adding Tiragolumab to Atezolizumab-Bevacizumab in 1L HCC shows promising results
Erman Akkus/X
Jan 25, 2025, 12:40

Erman Akkus: Adding Tiragolumab to Atezolizumab-Bevacizumab in 1L HCC shows promising results

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post about recent paper by Richard S Finn et al. on X:

“Adding Tiragolumab to Atezo-Beva in 1L of HCC MORPHEUS-Liver:

  • Anti-TIGIT, phase 1b–2
  • ORR: 43% vs. 11%
  • Serious adverse events: 53% vs. 56%
  • mPFS: 12.3 vs. 4.2 mo
  • mOS: 28.9 vs. 15.1 mo”

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

Authors: Prof Richard S Finn, Prof Baek-Yeol Ryoo, Prof Chih-Hung Hsu, Daneng Li, Prof Adam M Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Sami Mahrus, Matthew H Secrest, Colby S Shemesh, Nancy Yu, Stephen P Hack, Edward Cha, Prof Ed Gane

Erman Akkus: Adding Tiragolumab to Atezolizumab-Bevacizumab in 1L HCC shows promising results

Anti TIGIT atezolizumab Bevacizumab cancer cancer immunotherapy Erman Akkus HCC MORPHEUS-Liver trial mOS mPFS OncoDaily Oncology serious adverse events The Lancet Oncology Tiragolumab
Special Coverage
Blog
Apr 2, 2025, 11:14
FDA welcomes Martin A. Makary as the 27th Commissioner of the U.S. Food and Drug Administration
Science
Apr 2, 2025, 11:04
Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial
Science
Apr 2, 2025, 10:53
Diego A. Díaz García: Cross-priming is key in cancer immunotherapy
Science
Apr 2, 2025, 10:29
Bishal Gyawali: Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers
Blog
Apr 2, 2025, 10:15
IMF Regional Community Workshop to learn all about MM - International Myeloma Foundation
Blog
Apr 2, 2025, 10:10
Ready to coordinate Advisory Board in Basilicata to improve oncology research - Sbarro Health Research Organization
Blog
Apr 2, 2025, 10:07
Teresa Amaral: Discussing neoadjuvant therapy in skin cancer at the 27th International Dermatology Meeting
Blog
Apr 2, 2025, 10:05
Wafaa M Rashed: Personalized HIV Treatment in Africa
Career
Apr 2, 2025, 10:01
Karen Knudsen: I’ve taken the helm of Parker Institute for Cancer Immunotherapy (PICI) as CEO
Blog
Apr 2, 2025, 09:58
John F. Kurland presented about immuno-oncology therapies at the IO360 Summit
Blog
Apr 2, 2025, 09:54
ACC 2025 Clinical Trials to Watch with Deepak Bhatt - Mount Sinai Department of Medicine
Blog
Apr 2, 2025, 09:46
Orouba Almilaji: NATCAN - improving the quality of National Health Service cancer care in England and Wales